Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BDTX Stock Forecast 2026-2027
$1.97
Current Price
$112.88M
Market Cap
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to BDTX Price Targets
+610.7%
To High Target of $14.00
+407.6%
To Median Target of $10.00
+255.3%
To Low Target of $7.00
BDTX Price Momentum
-11.3%
1 Week Change
-30.1%
1 Month Change
-23.6%
1 Year Change
-18.9%
Year-to-Date Change
-60.1%
From 52W High of $4.94
+2.1%
From 52W Low of $1.93
📊 TOP ANALYST CALLS
Did BDTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Black Diamond is one of their latest high-conviction picks.
Latest BDTX Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, BDTX has a bullish consensus with a median price target of $10.00 (ranging from $7.00 to $14.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $1.97, the median forecast implies a 407.6% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BDTX Analyst Ratings
8
Buy
1
Hold
0
Sell
BDTX Price Target Range
Low
$7.00
Average
$10.00
High
$14.00
Current: $1.97
Latest BDTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BDTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 29, 2026 | BTIG | Robert Burns | Buy | Maintains | $11.00 |
| Mar 17, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Jan 16, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Dec 4, 2025 | Guggenheim | Neutral | Downgrade | $N/A | |
| Nov 18, 2025 | Piper Sandler | Kelsey Goodwin | Overweight | Assumes | $9.00 |
| Oct 16, 2025 | Stifel | Laura Prendergast | Buy | Reinstates | $8.00 |
| Oct 1, 2025 | Freedom Broker | Buy | Initiates | $N/A | |
| Sep 4, 2025 | Guggenheim | Buy | Initiates | $N/A | |
| Aug 11, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jul 1, 2025 | Raymond James | Sean McCutcheon | Outperform | Reinstates | $11.00 |
| Mar 18, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 7, 2025 | Stifel | Buy | Maintains | $N/A | |
| Nov 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 9, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 8, 2024 | Wedbush | Outperform | Reiterates | $N/A | |
| Sep 24, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 23, 2024 | Piper Sandler | Overweight | Maintains | $N/A | |
| Sep 18, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 10, 2024 | Wedbush | Outperform | Reiterates | $N/A | |
| Sep 4, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Black Diamond Therapeutics, Inc. (BDTX) Competitors
The following stocks are similar to Black Diamond based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Black Diamond Therapeutics, Inc. (BDTX) Financial Data
Black Diamond Therapeutics, Inc. has a market capitalization of $112.88M with a P/E ratio of 7.2x. The company generates $70.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of +28.4% and return on equity of -35.2%.
Valuation Metrics
Market Cap
$112.88M
Enterprise Value
$19.38M
P/E Ratio
7.2x
PEG Ratio
-0.1x
Price/Sales
1.6x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
+28.4%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+104.8%
Current Ratio
8.5x
Debt/Equity
17.1x
ROE
-35.2%
ROA
-18.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Black Diamond Therapeutics, Inc. (BDTX) Business Model
About Black Diamond Therapeutics, Inc.
What They Do
Develops therapies for genetically defined cancers.
Business Model
The company operates as a clinical-stage oncology firm, focusing on developing MasterKey therapies that specifically target oncogenic mutations in cancer patients. It generates revenue through the advancement of its drug candidates, such as silevertinib, which is in Phase 2 trials for non-small cell lung cancer and glioblastoma, as well as through licensing agreements like the one with Servier for another drug candidate.
Additional Information
Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics is committed to precision oncology, aiming to address the needs of patients with mutation-driven cancers. Its innovative approach seeks to minimize toxicity and enhance treatment efficacy for brain-related tumors.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
21
CEO
Dr. Mark A. Velleca M.D., Ph.D.
Country
United States
IPO Year
2020
Website
www.blackdiamondtherapeutics.comBlack Diamond Therapeutics, Inc. (BDTX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
May 27, 2026
By Ahan Chakraborty
Analyst Blog Plus
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
May 27, 2026
By Ahan Chakraborty
Analyst Blog Plus
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
May 27, 2026
By Ahan Chakraborty
Analyst Blog Plus
Latest News
Quick Summary
BDTX reported a strong Q1, with a cash runway extending to 2028, emphasizing silevertinib's clinical durability and CNS profile.
Why It Matters
BDTX's strong Q1 results and extended cash runway enhance confidence in silevertinib's potential, suggesting sustained investor interest and possible future growth in the biotech sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Black Diamond's May 2026 update on silevertinib indicates stable NSCLC response rates, CNS activity, and progress on dosing, though durability data is still in early stages.
Why It Matters
Black Diamond's update on silevertinib suggests promising NSCLC treatment potential, impacting future market position, but early durability data may introduce uncertainty for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Black Diamond is expanding its drug silevertinib into glioblastoma, enhancing long-term potential in CNS markets, while continuing to prioritize NSCLC in the short term.
Why It Matters
Black Diamond's expansion into glioblastoma could diversify its pipeline and increase potential revenue streams, enhancing long-term growth prospects alongside its NSCLC focus.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Black Diamond Therapeutics shares dropped following phase II data on silevertinib, indicating efficacy in NSCLC and CNS activity, but investors are cautious due to the dataset's early stage.
Why It Matters
Black Diamond Therapeutics' share drop reflects uncertainty around silevertinib's early phase II results, impacting investor confidence in the drug's future potential in NSCLC and CNS markets.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Black Diamond Therapeutics (NASDAQ: BDTX) reported that its investigational therapy, silevertinib, achieved a median progression-free survival of 15.2 months in Phase 2 trials for lung cancer patients.
Why It Matters
Positive Phase 2 results for silevertinib indicate potential for significant market impact in treating non-small cell lung cancer, potentially boosting Black Diamond's stock value and investor interest.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Black Diamond Therapeutics reported positive Phase 2 trial results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations. Data will be presented at ASCO on May 30, 2026.
Why It Matters
Positive Phase 2 trial results for silevertinib may boost Black Diamond Therapeutics' stock, indicating potential market growth in oncology, particularly for EGFR non-classical mutations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BDTX Stock
What is Black Diamond Therapeutics, Inc.'s (BDTX) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Black Diamond Therapeutics, Inc. (BDTX) has a median price target of $10.00. The highest price target is $14.00 and the lowest is $7.00.
Is BDTX stock a good investment in 2026?
According to current analyst ratings, BDTX has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BDTX stock?
Wall Street analysts predict BDTX stock could reach $10.00 in the next 12 months. This represents a 407.6% increase from the current price of $1.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Black Diamond Therapeutics, Inc.'s business model?
The company operates as a clinical-stage oncology firm, focusing on developing MasterKey therapies that specifically target oncogenic mutations in cancer patients. It generates revenue through the advancement of its drug candidates, such as silevertinib, which is in Phase 2 trials for non-small cell lung cancer and glioblastoma, as well as through licensing agreements like the one with Servier for another drug candidate.
What is the highest forecasted price for BDTX Black Diamond Therapeutics, Inc.?
The highest price target for BDTX is $14.00 from at , which represents a 610.7% increase from the current price of $1.97.
What is the lowest forecasted price for BDTX Black Diamond Therapeutics, Inc.?
The lowest price target for BDTX is $7.00 from at , which represents a 255.3% increase from the current price of $1.97.
What is the overall BDTX consensus from analysts for Black Diamond Therapeutics, Inc.?
The overall analyst consensus for BDTX is bullish. Out of 5 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are BDTX stock price projections?
Stock price projections, including those for Black Diamond Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 3:50 PM UTC